Literature DB >> 32547099

Pleomorphic Leiomyosarcoma of the Adrenal Gland in a Young Woman: A Case Report and Review of the Literature.

Yuanyuan Wang1, Yongliang Teng2, Shibo Na3, Ye Yuan1.   

Abstract

Leiomyosarcoma usually arises in the uterus, abdominal and urologic viscera, and walls of large and small blood vessels. However, primary adrenal leiomyosarcoma is extremely rare with only 39 cases previously reported in English-language literature. We report a case of a 29-year-old previously healthy woman with an incidentally found right adrenal-occupying lesion. CT scan revealed a right adrenal mass measuring 3.3×3.4 cm in size. The tumor was successfully removed by laparoscopic adrenalectomy. Postoperative histopathologic examination showed spindle cells arranged in interlacing fascicles with pleomorphism and a high mitotic rate. An immunohistochemical examination showed positive staining for SMA, desmin, vimentin and H-caldesmon, and the diagnosis of a well-differentiated adrenal leiomyosarcoma was established. The patient received no other oncological treatment after surgery and currently has no evidence of residual disease or tumor recurrence according to imaging follow-up.
© 2020 Wang et al.

Entities:  

Keywords:  adrenal gland; adrenal gland neoplasms; adrenalectomy; leiomyosarcoma

Year:  2020        PMID: 32547099      PMCID: PMC7263850          DOI: 10.2147/OTT.S254162

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


Introduction

Leiomyosarcoma is a malignant mesenchymal tumor composed of cells showing distinct features of the smooth muscle lineage.1 The most common anatomic sites are the uterus, abdominal and urologic viscera, and walls of large and small blood vessels. Occasionally, these tumors arise in bone, in somatic soft tissues and extremely rarely in the adrenal gland.2,3 In 1981, Choi SH et al reported the first case of primary adrenal leiomyosarcoma (PAL). There are only 39 cases reported in English-language literature so far. Definitive diagnosis of PAL is usually achieved only after pathologic examination of the surgical specimen. Due to the development and wide use of imaging techniques such as computed tomography (CT) and ultrasonography, unexpected and special incidentaloma lesions can be detected more easily. Herein, we describe a case of a young woman with PAL without any discomfort. In addition, we report on our analysis of pathological features and corresponding data extracted from the 39 reported cases. Our aim is to share our experiences with rare tumors and discuss the epidemiology, anatomical localization, and diagnosis and current treatment strategies.

Case Report

A 29-year-old previously healthy Chinese woman incidentally found a right suprarenal mass by abdominal ultrasound on a preemployment examination. The patient denied systemic symptoms, pain, fever, anorexia, and other notable medical history. Physical examination did not reveal any significant abdominal tenderness, lymphadenopathy or other findings. Routine laboratory examinations were normal, including complete blood count, renal function and electrolyte levels. All the hormonal data showed that 24-h urine cortisol and plasma aldosterone to renin ratio were within normal limits, as were catecholamines and ACTH levels. Cortisol post 1 mg dexamethasone was 0.5 μg/dl (normal < 1.8). HIV-1 and HIV-2 antibody tests were nonreactive. Abdominal ultrasound showed the presence of a diffusely hypoechoic, homogeneous mass in the region of the right suprarenal area measuring 4.2×2.5 cm. We proceeded with computed tomography (CT) of the abdomen, and it revealed a well-defined tumor originating from the right adrenal gland that was 3.3×3.4 cm in size; the tumor, exerted pressure on the hepatic vein without evidence of regional adenopathies or infiltration of surrounding tissues. Contrast-enhanced CT showed moderate enhancement with irregular non-enhanced areas within, suggesting malignancy (Figure 1). A positron emission tomography/computed tomography (PET/CT) scan with 18F-FDG was performed, which revealed an exclusive and high uptake in the right adrenal tumor lesion.
Figure 1

Preoperative abdominal contrast-enhanced CT scan showed a well-circumscribed heterogeneously mass in the right suprarenal areal (arrow). (A) Axial sections and (B) coronal sections.

Preoperative abdominal contrast-enhanced CT scan showed a well-circumscribed heterogeneously mass in the right suprarenal areal (arrow). (A) Axial sections and (B) coronal sections. A right adrenalectomy was scheduled and performed uneventfully. Intraoperatively, we found a solid mass that almost completely replaced the right adrenal gland adherent to the posterior wall of the inferior vena cava (IVC). We explored the IVC and adjacent organs, and no tumor invasion was detected. Tissue margins were negative. Postoperatively her vital signs remained stable and as there were no complications. No adjuvant therapy and other medication was given, and the patient was discharged 2 days after surgery. Currently, she is alive and doing well, without evidence of recurrence or distant metastasis at the 12-month follow-up. Gross pathological examination showed a well-circumscribed and partially encapsulated solid tumor weighing 37.5 g and measuring 5.5×5×3.2 cm in maximum dimension. The cut surface was nodular and grayish white in color with few mucoidal, hemorrhagic and necrotic areas. The normal adrenal gland was displaced by the tumor and presented at the edge of the tumor (Figure 2). Microscopically, the adrenal gland was compressed, but not invaded by the spindle cell tumor, which was arranged in interlacing fascicles (Figure 3A). Tumor cells were elongated with eosinophilic fibrillary cytoplasm with marked pleomorphism of the nuclei, with up to 8–10 mitoses/10 high power fields (Figure 3B). No infiltrated lymph nodes were found. An immunohistochemical examination showed positive staining for SMA, desmin (Figure 3C), vimentin, and H-caldesmon (Figure 3D), and negative staining for S-100, CD 117, Dog-1, ER and PR. The Ki-67 proliferation index was approximately 40% in the hot spot. Based on these data, the final diagnosis was confirmed as a primary adrenal leiomyosarcoma.
Figure 2

Macroscopic features of the tumor showed a well-circumscribed and partially encapsulated solid tumor measuring 5.5×5×3.2 cm in maximum dimension. The normal adrenal gland was displaced by the tumor and presented at the edge of the tumor.

Figure 3

Microscopic details of the tumor. (A) The interlacing bundle and fascicles of the tumor (arrowhead) and compressed adrenal tissue (arrow). (H&E, × 100). (B) Leiomyosarcoma with nuclear pleomorphism and giant cell formation with mitotic activity in the range of 8–10 mitoses/10 high power fields (H&E, × 400). (C) Immunohistochemical staining for desmin is positive (× 100). (D) Immunohistochemical examinations showed strong immunoreactivity for H-caldesmon (× 100).

Macroscopic features of the tumor showed a well-circumscribed and partially encapsulated solid tumor measuring 5.5×5×3.2 cm in maximum dimension. The normal adrenal gland was displaced by the tumor and presented at the edge of the tumor. Microscopic details of the tumor. (A) The interlacing bundle and fascicles of the tumor (arrowhead) and compressed adrenal tissue (arrow). (H&E, × 100). (B) Leiomyosarcoma with nuclear pleomorphism and giant cell formation with mitotic activity in the range of 8–10 mitoses/10 high power fields (H&E, × 400). (C) Immunohistochemical staining for desmin is positive (× 100). (D) Immunohistochemical examinations showed strong immunoreactivity for H-caldesmon (× 100).

Discussion

PAL is an extremely rare nonfunctional mesenchymal tumor, and to the best of our knowledge, there have only been 39 previously published cases of PAL in English-language literature. The clinicopathologic characteristics of these cases are summarized in Table 1. PAL is mostly found in middle-aged adults. The age at first diagnosis ranges from 14 to 79 years, with a mean of 54.2 years. Of these patients, 77.5% have been ≥ 40 years of age. PAL is evenly distributed between the sexes with cases involving 21 women and 19 men. In addition, there does not appear to be any laterality preference, as right-sided and left-sided tumors occur with similar frequency. There have only been two cases of bilateral lesions,4,5 but it is not known whether the bilateral tumors were both primary or if one had metastasized to the other adrenal gland.
Table 1

Clinicopathologic Characteristics of Primary Adrenal Leiomyosarcoma

Author, YearAge, y/SexPresentationSideSize (cm)TreatmentOutcome (months)ExtensionPathologic Characteristics of Known Cases of PAL in the Literature
Our case29/FIncidental findingR5.5Adx12m AWODNonePleomorphic+ SMA/desmin/vimentin/H-caldesmon+
Sakellariou M et al, 20202662/MIncidental findingL13Adx; RT+CT31m, alive with bone, lung and liver metastasisNone (preoperative); bone metastasis (postoperative after 3 months)SMA/desmin+
Nerli RB et al, 20192727/MBack painL9AdxN/DNoneDesmin/H-caldesmon+
Doppalapudi SK et al, 2019670/MAbdominal varices+EBLER9Adx + Nx+ thrombectomy+ cavatomy14m, deceasedIVC (preoperative); lung metastasis (postoperative after 12 months)SMA/desmin/vimentin/H-caldesmon+
Mulani SR et al, 20182850/MAbdominal pain + weight lossL8.1CT+RTN/DLiver and lung metastasisPleomorphic+ desmin +
Onishi T et al, 20162934/MFlank painR5.2Adx+ Nx+ Ldx+ partial hepatic lobectomy10m AWODIVC+AOPleomorphic+ SMA+
Zhou Y et al, 20152449/FAbdominal pain+ back painL8Adx6m AWODNoneSMA/desmin/vimentin+
Quildrian S et al, 20153044/FAbdominal painR12Adx36m, AWODNonePleomorphic+ SMA/desmin/vimentin/H-caldesmon/HHF+
Nagaraj V et al, 20153161/MFlank painL17AdxN/DNonePleomorphic+ desmin/vimentin+
Wei J et al, 20143257/FIncidental findingL8Adx; tumor resection+CT29m, AWODNone (preoperative); recurrence (postoperative after 17 months)Pleomorphic+ SMA/desmin/vimentin+
Oztürk H et al, 20143370/FFlank painR7.8Adx+ cavatomy6m, metastasisIVCPleomorphic+ SMA/desmin +
Lee S et al, 20143428/MFlank pain+weight lossR15Adx18m, AWODNonePleomorphic+ SMA/desmin +
Gulpinar MT et al, 20143548/MFrequent urinationR11Adx8m, AWODNoneSMA/vimentin+
Bhalla A et al, 20143645/MBack and groin pain+weight lossR11CT9m, metastasisLiver metastasisSMA/desmin+
Alam MM et al, 20143735/FFlank painL8.5AdxN/DNoneND
Deshmukh SD et al, 20131760/FFlank painL5.2Adx21m, AWODNonePleomorphic+ SMA/desmin/vimentin+
Shao IH et al, 20123866/MAbdominal fullness + nauseaL9.5Adx + thrombectomy18m, AWODRenal veinSMA/desmin +
Karaosmanoglu AD et al, 20103963/MAbdominal pain+EBLERN/DCT3m, deceasedIVCDesmin/vimentin/actin+
Kanthan R et al, 20124028/FAbdominal painL16.5Adx+Nx+partial diaphragmatic resectionN/DNonePleomorphic+ SMA/vimentin+;desmin-
Liu SV et al, 2012779/FSubcostal painL6.3Adx12m, AWODN/DN/D
Van Laarhoven HWM et al, 20094178/MHemithorax painLN/DCT+RT11days, deceasedMultiple metastasesSMA/vimentin/actin+
Hamada S et al, 2009462/FFlank painBR(8)L(4)Bil Adx+CT+RFA+RT16m, deceasedNone (preoperative); multiple metastasis (postoperative)SMA+
Mencoboni et al, 20082275/FAbdominal pain+ loin pain.R8Adx12m, AWODN/DPleomorphic+ SMA/desmin/actin+
Goto J et al, 20082073/FFlank pain+progressive hypertensionR8Adx+Nx+cavotomy10m, AWODAOSMA/NSE +
Wang TS et al, 2007864/FNon-productive cough+ EBLER14.2Adx+thrombectomy+cavotomy10m, AWODIVC, right atriumSMA/desmin+
Mohanty SK et al, 20071847/FFlank painL10Adx+Nx+RT9m, alive with lung and liver metastasisNone (preoperative); lung and liver metastasis (postoperative after 9 months)Pleomorphic+SMA/desmin/H-calponin/actin+
Lee CW et al, 20064249/MFlank painL3Adx10m, AWODNoneDesmin+
Wong C et al, 2005957/MGroin pain +cold feetLN/DAdx+particial Nx+ thrombectomy6m, recurrence, deceasedIVC, iliac veins and right atriumN/D
Candanedo-González FA, 20054359/FFlank pain+weight lossL16Adx24m, AWODNone (preoperative); recurrence and liver metastasis (postoperative after 12 months)Pleomorphic+desmin/vimentin/actin+
Linos D et al, 2004514/FIncidental findingBR(3.5)L(4)Bilateral Adx14m, AWODNoneSMA/vimentin/actin/HHF35+
Kato T et al, 20044459/MFlank pain+back pain.L10Adx+Nx+thrombectomy+RT6m, deceasedIVC+renal vein (preoperative); bone and liver (postoperative after 1 month)Pleomorphic+ SMA/desmin/vimentin+
Thamboo TP et al, 20032168/FLoin pain+feverR12.5Adx+Nx12m, AWODNonePleomorphic+ SMA/desmin/vimentin/actin+
Lujan MG et al, 20032363/MEnlarging RUQ massR25Preoperative CT+Adx+Nx+partial hepatic lobectomy+ cholecystectomyDeceased shortly aftersurgeryInvaded AO+lung metastasisPleomorphic+ desmin/vimentin/H-calponin +;SMA/actin -
Matsui Y et al, 20021161/FFlank pain+feverRN/DAdx+Nx+thrombectomy1m, deceasedAO+IVC+right atriumSMA+
Etten B et al 20011073/FEBLE+abdominal painR27Palliative + supportive care3 weeks, deceasedIVC+AOSMA+
Boman F et al, 19974529/MAutopsyL0.8NoneN/DNoneSMA/HHF35+
Zetler PJ et al, 19954630/MAbdominal painL11Adx20m, AWODNonePleomorphic+ SMA/actin+
Hayashi J et al, 19954755/FAbdominal pain+feverRN/DAdx+Nx52m, AWODIVC+right atrium+hepatic veinN/D
Lack EE et al, 19911949/MFlank painR11Adx+Nx;CT+RT9m, alive with bone metastasesNone (preoperative); bone(postoperative after 3 months)Pleomorphic+ SMA/vimentin/actin+
Choi SH et al, 19814850/FFlank painL16Adx+partial Nx12m, AWODNoneN/D

Abbreviations: Adx, adrenalectomy; AO, adjacent organ; AWOD, alive without disease; CT, chemotherapy; EBLE, edema in both lower extremities; IVC, inferior vena cava; Lymx, lymphadenectomy; NSE, neuron-specific enolase; Nx, nephrectomy; N/D, not disclosed; PAL, primary adrenal leiomyosarcoma; RFA, radiofrequency ablation; RT, radiation therapy; RUQ, right upper quadrant; SMA, smooth muscle actin.

Clinicopathologic Characteristics of Primary Adrenal Leiomyosarcoma Abbreviations: Adx, adrenalectomy; AO, adjacent organ; AWOD, alive without disease; CT, chemotherapy; EBLE, edema in both lower extremities; IVC, inferior vena cava; Lymx, lymphadenectomy; NSE, neuron-specific enolase; Nx, nephrectomy; N/D, not disclosed; PAL, primary adrenal leiomyosarcoma; RFA, radiofrequency ablation; RT, radiation therapy; RUQ, right upper quadrant; SMA, smooth muscle actin. Symptoms are mainly secondary to the mass effect of the tumor and local invasion. The most common presenting symptom is flank pain or abdominal pain in approximately 64% of patients. If the tumor extends into the IVC or the large tumor compresses the IVC, patients may present with IVC involvement, and experience obstructive symptoms such as lower extremity edema, spider angiomata, abdominal varices, and even altered sensation in the lower limbs.6–10 In a rarely case, the tumor ruptured suddenly, and the patient presented with severe and acute abdominal pain.11 Because tumors are located in the retroperitoneum, and are often nonfunctional, they often grow to large sizes prior to noticeable symptoms. The size of the PAL at presentation has ranged from 0.8 to 27 cm (mean, 10.2 cm), with 78.4% of tumors larger than 6 cm. Adrenal masses detected incidentally during radiological investigations account for 4%.12 Although there are no definite features that can be used to diagnose PAL, imaging examination is useful for identifying the tumor size, location and metastasis, and evaluating its extent in relation to its surrounding structures, as well as distinguishing between potentially benign and malignant lesions. In a series of 705 patients with adrenal incidentalomas, it was demonstrated that unenhanced CT attenuation >10 and size greater than 7 cm had a high sensitivity for malignancy.13 There is a growing consensus, however, that the size should not be used to differentiate malignant from benign adrenal tumor. Modern imaging techniques such as magnetic resonance imaging (MRI) and 18F-FDG-PET represent the state of the art in adrenal imaging, which have greater sensitivity and specificity in establishing malignant versus benign diagnosis. MRI provides a more precise estimation than CT in the detection of the tumor origin and location to local structures due to its high-quality soft tissue resolution. Generally speaking, malignant masses are denser than benign masses, and often appear hyperintense on T2-weighted images on account of their higher fluid content.14 Multiplanar postcontrast imaging is also useful to evaluate the extent of vascular involvement and to distinguish tumor from bland thrombus.15 Evaluation using FDG-PET has a high sensitivity for detecting malignancy; increased FDG accumulation can be seen in all cases of PAL that performed FDG-PET. Hamada et al reported that the metastasis was detected by PET before it was found by CT.4 A core biopsy may be performed with radiological or ultrasound assistance prior to surgical resection. The current guidelines for the management of adrenal tumors recommend that the tumor should be confirmed to be hormonally inactive (in particular, a pheochromocytoma has been ruled out) prior to biopsy.16 In addition, nonfunctional primary adrenal cortical carcinoma should also be considered as a differential diagnosis prior to an adrenal biopsy because tumor seeding can take place. There is currently no tumor marker or imaging that can aid to distinguish PAL nodules from other adrenal nodules nor is there an identified characteristic genetic rearrangement or specific endocrinological change associated with this neoplasm. The diagnosis of PAL is still completely dependent on histological and immunohistological evaluations after surgery. Histologically, retroperitoneal smooth muscle tumors containing 5 or more mitoses per 50 high power fields are classified as malignant. The presence of tumor cell necrosis is also strongly suggestive of malignancy.17 The typical histologic features of leiomyosarcomas include intersecting, sharply marginated fascicles of spindle cells with abundant eosinophilic cytoplasm and elongated and hyperchromatic nuclei. In many cases, coagulative necrosis and hemorrhage are common features. Varying degrees of nuclear hyperchromasia and pleomorphism usually manifest.15 Pleomorphic leiomyosarcomas that resemble any undifferentiated soft tissue sarcomas show moderate-to-high anaplasia as in the index cases and need a panel of immunohistochemical stains to arrive at a definitive diagnosis.18 Pleiomorphic subtypes are not uncommon with 18 known cases (45%). Some cases did not reveal pleiomorphism, but prominent atypical nuclei and bizarre giant cells were described. This implies that leiomyosarcoma should be considered in the cases of an adrenal mass with malignant spindle and pleomorphic cells; however, poor prognosis is not necessarily indicated with tumors with bizarre giant and pleomorphic cells. Tumor cells are widely presumed to arise from the smooth muscle wall of the inferior vena cava, central adrenal vein, and its branches.19 Direct infiltration of leiomyosarcoma cells was not observed microscopically in adjacent adrenal tissue in five cases. Some findings revealed that the tumor was surrounded by a thin rim of fibrous tissue and bordered the grossly identifiable adrenal gland. Therefore, we can further confirm that leiomyosarcoma most likely arises from adrenal blood vessels but not the adrenal gland.8,20,21 Immunohistochemistry is an extremely useful tool not only for determining tumor type, but also for differentiating leiomyosarcomas from other tumors (including melanoma, rhabdomyosarcoma, mesotheliomas and other sarcomas). Conventional leiomyosarcomas show strong reactivity for smooth muscle markers such as smooth muscle actin and/or muscle specific actin in 90–95% of cases and desmin in 70–90% of cases.17 However, due to the lack of such detection in many cases of PAL, we cannot obtain reliable statistical data. Surgical resection with wide negative margins constitutes the predominant mode of therapy,16 and has the greatest impact on survival. Since tumors are typically large at diagnosis and likely to invade the IVC, it is important to carefully resect any possibly involved tissue. It is worth noting that some patients develop pulmonary embolism after surgery, so we should strengthen this aspect of care for patients.8,22 The role of chemotherapy or radiation is not well defined. Although some reports suggested that radiation therapy could alleviate symptoms for patients with metastasis and ensure improved local control,2 the sensitivity was generally poor. Kato T et al21 performed palliative radiation therapy for the patient with cervical spine metastasis, but it showed almost no effect. Systemic chemotherapy may delay local recurrence if given as adjuvant/neoadjuvant treatment, but there are lack of randomized trial data indicating a survival benefit for patients.2 In one case reported by Lujan MG et al,23 the patient received preoperative chemotherapy, resulting in considerable reduction of the size of the lung mass; however, the adrenal mass continued to grow. Given the rarity of the tumor, assessment of its prognosis remains difficult, but venous thrombosis, adjacent organ invasion and distant metastases were proposed to be predictors of an unfavorable outcome.7,24 A prospective study suggested that 55% of patients with leiomyosarcomas of somatic soft tissues developed metastasis or died within 3 years.25 We found that of the 40 patients, 7 died within six months. Because only limited clinical data are currently available on PAL, our data offer some important information on the clinical and therapeutic aspects of this rare disorder to increase clinician vigilance.

Conclusion

In conclusion, PAL is a rare mesenchymal neoplasm that most likely arises from the IVC, central adrenal vein and its branches. The tumors may grow to large sizes before incidental detection at imaging or palpation. Patients presenting with symptoms from these tumors might have large tumors that have invaded adjacent structures or extended into the IVC. Diagnosis in an advanced stage contributes to a poor prognosis. Surgical resection with clear margins remains the mainstay of treatment.
  48 in total

Review 1.  The clinically inapparent adrenal mass: update in diagnosis and management.

Authors:  Georg Mansmann; Joseph Lau; Ethan Balk; Michael Rothberg; Yukitaka Miyachi; Stefan R Bornstein
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

2.  Primary adrenal leiomyosarcoma with inferior vena cava extension in a 70-year-old man.

Authors:  Sai K Doppalapudi; Tejash Shah; Valerie A Fitzhugh; Vladislav Bargman
Journal:  BMJ Case Rep       Date:  2019-03-31

3.  Primary adrenal leiomyosarcoma in an adult female.

Authors:  M M Alam; M F Naser; M F Islam; M A Rahman
Journal:  Mymensingh Med J       Date:  2014-04

Review 4.  Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance.

Authors:  Giovanna Muscogiuri; Maria Cristina De Martino; MariaRosaria Negri; Claudia Pivonello; Chiara Simeoli; Francesco Orio; Rosario Pivonello; Annamaria Colao
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

5.  Surgery for cavoatrial extension of malignant tumors.

Authors:  J Hayashi; H Ohzeki; S Tsuchida; Y Fujita; S Tatebe; O Namura; S Eguchi; M Iwafuchi
Journal:  Thorac Cardiovasc Surg       Date:  1995-06       Impact factor: 1.827

Review 6.  Leiomyosarcoma.

Authors:  César Serrano; Suzanne George
Journal:  Hematol Oncol Clin North Am       Date:  2013-08-26       Impact factor: 3.722

7.  Primary adrenal leiomyosarcoma: A case report.

Authors:  Maria Sakellariou; Dionysios Dellaportas; Eirini Grapsa; Menelaos Tzikanoulas; Athanasios Dellis; Theodosios Theodosopoulos; Constantinos Nastos
Journal:  Mol Clin Oncol       Date:  2020-01-24

Review 8.  Three uncommon adrenal incidentalomas: a 13-year surgical pathology review.

Authors:  Rani Kanthan; Jenna-Lynn Senger; Selliah Kanthan
Journal:  World J Surg Oncol       Date:  2012-04-27       Impact factor: 2.754

9.  Primary leiomyosarcoma of the adrenal gland.

Authors:  B Etten; M G van Ijken; W J Mooi; M Oudkerk; A N van Geel
Journal:  Sarcoma       Date:  2001

10.  Vena Cava ınvasion by Adrenal Leiomyosarcoma.

Authors:  Hakan Oztürk
Journal:  Rare Tumors       Date:  2014-06-23
View more
  1 in total

Review 1.  Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation.

Authors:  Anca Maria Istrate-Ofiţeru; George Lucian Zorilă; Dan Ruican; Ana Maria Petrescu; Elena Iuliana Anamaria Berbecaru; Gabriela Camelia Roşu; Răzvan Grigoraş Căpitănescu; Rodica Daniela Nagy; Liliana Cercelaru; Antonie Edu; Dominic Gabriel Iliescu; Roxana Cristina Drăguşin
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.